Sarah Burkett, MD
Family Medicine · Novi, MINPI 1821309451
Payments from drug & device makers
Across 165 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$666
- AstraZeneca$531
- Pfizer$267
- Lilly USA, LLC$200
- Merck$149
- Boehringer Ingelheim$126
- plus $765 from 24 others
What the payments were for
- Food & beverage$2,704100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $666 |
| AstraZeneca | 33 | $531 |
| Pfizer | 19 | $267 |
| Lilly USA, LLC | 13 | $200 |
| Merck | 13 | $149 |
| Boehringer Ingelheim | 6 | $126 |
| GSK | 5 | $84 |
| Johnson & Johnson | 4 | $59 |
| Kaleo, Inc. | 4 | $56 |
| Amarin Pharma, Inc. | 4 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Abbott | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Exact Sciences | 2 | $34 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Dynavax Technologies Corporation | 2 | $24 |
| Olympus America Inc. | 1 | $24 |
| Vertex | 1 | $23 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Amgen | 1 | $16 |
| Cranial Technologies, Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Melinta Therapeutics, LLC | 1 | $11 |
How this compares
$2,704 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 43 | $60,405 |
| TrulicityDulaglutide | 25 | $47,110 |
| MounjaroTirzepatide | 24 | $35,373 |
| OzempicSemaglutide | 19 | $32,641 |
| RybelsusSemaglutide | 11 | $28,659 |
| XareltoRivaroxaban | 24 | $28,311 |
| JardianceEmpagliflozin | 24 | $25,692 |
| JanuviaSitagliptin Phosphate | 15 | $22,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $17,541 |
| FarxigaDapagliflozin Propanediol | 11 | $14,387 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $9,755 |
| PaxlovidNirmatrelvir/Ritonavir | 15 | $6,891 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 25 | $5,437 |
| MyrbetriqMirabegron | 12 | $5,349 |
| Atorvastatin Calcium | 404 | $4,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $200 | $82,48349 claims |
| PfizerEliquis, Paxlovid | $267 | $67,29658 claims |
| Novo NordiskOzempic, Rybelsus | $666 | $61,30030 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $84 | $32,73354 claims |
| Johnson & JohnsonXarelto | $59 | $28,31124 claims |
| Boehringer IngelheimJardiance | $126 | $25,69224 claims |
| MerckJanuvia | $149 | $22,18515 claims |
| AstraZenecaFarxiga | $531 | $14,38711 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $5,34912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Novi
- Marshall SackNovi$53K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.